Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
VTRS | NASDAQ | USD | Real-time | |
1VTRS | Milan | EUR | Real-time | |
VIA1 | Xetra | EUR | Delayed | |
VIA1 | TradeGate | EUR | Delayed | |
VIA1 | Frankfurt | EUR | Delayed | |
VTRSI | Vienna | EUR | Real-time |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Mark W. Parrish | 67 | 2009 | Independent Vice Chairman & Lead Independent Director |
Melina E. Higgins | 56 | 2013 | Independent Non-Executive Chairman |
Scott Andrew Smith | 61 | 2022 | CEO & Director |
Harry A. Korman | 67 | 2001 | Independent Non-Executive Director |
Wyllie Don Cornwell | 76 | 2020 | Independent Director |
James Marshall Kilts | 76 | 2020 | Independent Director |
Elisha Wade Finney | 63 | 2022 | Independent Director |
Leo Groothuis | 52 | 2023 | Independent Director |
Rajiv Malik | 63 | 2007 | Director |
JoEllen Lyons Dillon | 60 | 2014 | Independent Non-Executive Director |
Richard A. Mark | 70 | 2020 | Independent Non-Executive Director |
Rogerio Vivaldi Coelho | 60 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review